State of pharmacy, Pharmaceuticals & supplements: mid-2026. Concierge pharmacies, Granata and Meitheal driving positive change in pharma, Theralogix's growth year, Bird & Be partner with Kindbody. None of the organizations or individuals mentioned in this article reviewed nor had editorial control over its content. Inside Reproductive Health considered some information about sponsors included in its Business Intelligence Hub. By Inside Reproductive Health Specialty pharmacies continued emphasizing high-touch support, 24/7 pharmacist access, nationwide shipping, and coordination with fertility clinic protocols. Pharmaceutical companies advanced fertility-related pipelines, including gonadotropins, ovarian response programs, and reproductive injectable portfolios. Supplement companies expanded around physician-recommended formulations, third-party certification, provider programs, and retail accessibility. Consumer-facing fertility supplement brands also moved further into mainstream retail channels, making preconception and fertility support products more visible outside the fertility clinic. Mandell's Focused on Concierge Service, Says MedCity News Mandell's role in the fertility ecosystem is especially relevant because medication timing, dosing clarity, and refill coordination are central to the patient experience during ovarian stimulation and other fertility treatment cycles. The company's service model emphasizes pharmacist availability, medication education, and logistics support for patients managing complex fertility medication regimens. Mandell's reflects a high-touch model centered on medication access, patient communication, and coordination with clinic-directed treatment plans. Its strategic relevance is tied less to product ownership and more to operational execution: helping patients receive, understand, and administer fertility medications on the timelines required for treatment. Granata Bio's GEP Joint Venture and GRACE Phase III Enrollment In October 2025, Granata Bio and Georgetown Equity Partners announced a joint venture to develop a next-generation form of follicle-stimulating hormone. The program is based on hypoglycosylated recombinant FSH technology licensed from the University of Colorado Anschutz and is intended to explore a differentiated approach to ovarian stimulation within fertility treatment. Granata also advanced clinical development activity for its investigational gonadotropin program. In December 2025, the company reported strong enrollment momentum in its pivotal Phase III GRACE study, which is evaluating an investigational gonadotropin for assisted reproductive technology. The study's progress supports Granata's position as a fertility pharmaceutical company moving beyond early-stage pipeline activity into later-stage clinical evaluation. The company's broader platform also includes reproductive health assets and leadership with fertility pharmaceutical experience. Granata's website lists a leadership team focused on reproductive health development, commercialization, and operations, supporting the company's positioning as a fertility-focused biopharmaceutical organization. Meitheal Fertility Expands Injectable Portfolio Meitheal Pharmaceuticals' broader injectable portfolio continued expanding. The company has a portfolio of more than 70 FDA-approved injectable products, with additional products in development, clinical trials, and FDA review. While not every product is fertility-specific, this scale is relevant to Meitheal Fertility because injectable manufacturing, regulatory experience, and commercialization infrastructure are important for fertility medications used in IVF and related treatment protocols. Meitheal brought generic fertility medications to market, including gonadotropin-releasing hormone antagonists and fertility-related injectable products. In the fertility pharmacy and pharmaceuticals landscape, Meitheal's strategic relevance is tied to product availability, injectable medication infrastructure, and the potential to support more affordable fertility medication options for clinics and patients. Theralogix Expands Supplement Portfolio Following Leadership Transition and Record Growth Year Theralogix continued building its position as an evidence-based supplement company serving fertility, reproductive health, urology, and adjacent wellness categories. In January 2026, Theralogix announced a leadership transition following a record year of growth, with founding CEO Jay Hammer moving to CEO Emeritus, Andreas Wolf appointed Chief Executive Officer, and Christopher Good elevated to President. The leadership announcement also highlighted planned product expansion. Theralogix identified new products including OvaNAD+(TM), AgeRx(TM), TreBiome(TM), and Androsyn(TM), extending the company's portfolio across ovarian health, healthy aging, microbiome support, and men's health. For fertility patients and clinicians, OvaNAD+(TM) is especially relevant because it is positioned around ovarian health and egg-quality support. Theralogix also maintained brand visibility through health and wellness media recognition. In 2026, Exverus by Brainlabs won a MediaPost Planning & Buying Award for its "Wellness Women Can Trust" campaign for Theralogix, a campaign focused on reaching women seeking trustworthy information around fertility and menstrual health. Theralogix also continued emphasizing provider relationships through its partner program for healthcare professionals and practices, including referral-code, wholesale, and provider-support options. The company's model reflects a supplement category increasingly shaped by physician recommendation, third-party certification, medical advisory input, and patient-facing education. Bird&Be Expands Fertility Supplements and At-Home Testing Through Ulta Beauty Rollout Bird&Be continued expanding consumer access to fertility-support products through retail distribution, at-home testing, and patient-facing affordability initiatives. The company's public materials position Bird&Be around fertility supplements, ovulation support, sperm health products, and at-home fertility testing for people trying to conceive. Bird&Be's most visible recent expansion centered on its Ulta Beauty retail rollout. The company announced that Bird&Be fertility supplements and at-home testing kits would be available through more than 300 Ulta Beauty stores and Ulta.com, bringing fertility-support products into a mainstream beauty and wellness retail channel. In 2026, Bird&Be also continued community-oriented affordability efforts. The company launched a Fertility Fund Giveaway offering two winners $3,500 each toward fertility-treatment costs, including an in-clinic credit at Kindbody. The initiative connected Bird&Be's at-home fertility support positioning with broader patient access and affordability themes in the fertility market. Was Your Org Not Included? Don't let your company miss out again. Your competitors were covered because they are IVF Heroes Universe sponsors. Over 60 leading fertility companies are leaders in the IVF Heroes Universe, isn't yours? Year-long sponsorship is only $2,295 for the entire year, but get in now, before prices go up. None of the organizations or individuals mentioned in this article reviewed nor had editorial control over its content. Inside Reproductive Health considered some information about sponsors included in its Business Intelligence Hub.

How employers are balancing impact and affordability in reproductive health benefits: A conversation with The RealReal. March 23, 2026 Last week, Kindbody Group had the incredible opportunity to present at The Conference Board's Employee Healthcare Conference in New York, a premier gathering of industry leaders, forward-thinking employers, and benefits executives. The event served as a dynamic forum for exploring the latest trends and innovations shaping the future of employee healthcare. Kindbody's Founding Physician and Chief Innovation Officer Dr. Fahimeh Sasan took the stage alongside its valued employer partner, Mindy Christopher, Benefits Manager at The RealReal, to discuss one of today's most pressing topics: how employers can balance rising cost pressures with the need to deliver meaningful, high-quality care that drives employee retention and engagement. Together, they shared a candid look at what it takes to drive impact, from aligning on outcomes that matter to building solutions that are both clinically effective and financially sustainable. In addition to the conversations on stage, its team spent time connecting with employers at its booth, providing a valuable, real-time pulse on what is top of mind across the market. A few themes came up consistently: Cost control is the top priority. Employers are under increasing pressure to manage healthcare spend, with many sharing that CFOs are more involved than ever and holding teams accountable for measurable outcomes. There is a clear expectation that solutions demonstrate impact, both in terms of clinical outcomes and cost savings. As part of this focus, employers are also looking for greater transparency and alignment in how solutions are priced and utilized, with models such as Kindbody's approach of only charging for services actually provided, rather than a PEPM structure, resonating as a way to ensure spend is directly tied to value delivered. A shift toward efficiency over expansion. Rather than adding more point solutions, employers are focused on optimizing and better utilizing existing benefits. This increasingly includes auditing their current vendor ecosystem to identify underperforming or redundant solutions and, where appropriate, consolidating or replacing them with more impactful, integrated options that deliver stronger outcomes and clearer value. A shift toward efficiency over expansion was also evident, with Mindy sharing that at The RealReal they took a holistic look across their vendor ecosystem, evaluated utilization across programs, and made intentional trade-offs to reallocate existing dollars, ultimately enabling them to add Kindbody without increasing their overall budget. Family-building benefits continue to be one of the most impactful tools employers have for both recruiting and retaining talent. As competition for top talent intensifies, employees are increasingly evaluating benefits as a key factor in where they choose to work and whether they stay. As Mindy shared, "I've actually heard somebody say, 'I wanted to leave, but now with this benefit, I can't because I won't find it anywhere else.'" She noted that from a talent acquisition and retention perspective, fertility and family-building benefits can be a meaningful differentiator and "a wonderful retention strategy." Beyond retention, she emphasized the life-changing impact of these benefits, sharing that "there's people who may not have had an option before, and now they do have options," and that "it makes me feel like what I do is actually changing somebody's life - because it actually is." She also highlighted how powerful it is to hear directly from employees, including those who share their experiences with senior leadership such as the CEO, CPO, and CFO. Optionality is key. Employers are looking to provide more choice and flexibility in how employees access care, recognizing that one size does not fit all. This includes offering multiple pathways to care, more personalized benefit experiences, and solutions that can adapt to diverse employee needs. At the same time, there is a tension between offering optionality and avoiding unnecessary complexity, making thoughtful curation and guidance increasingly important. As Mindy shared in the context of menopause care, while it is not something they currently offer, it is a benefit they anticipate wanting to provide in the future as their workforce ages. Dr. Sasan noted that "the number one word I hear from women who have had appropriate menopause care is 'life-changing,'" adding that employers should be able to support "life-changing moments in our 40s and 50s when we feel more like ourselves." Taken together, the conversations at The Conference Board and insights from The RealReal reflect a clear direction for employers: reproductive health benefits must deliver measurable value, support employee needs, and operate within increasingly defined financial constraints. As employers continue to refine their strategies, those that can balance affordability with impact, while also supporting recruitment, retention, and employee experience, will be best positioned for long-term success. Kindbody. Kindbody is a new generation of women's health and fertility care. Providing you with the information you need to take control of your health and make the decisions that are right for you. Kindbody Group is a community of healthcare providers, fertility specialists, and women who get it. Kindbody Group is on a mission to democratize and de-stigmatize women's health and fertility care, making it accessible, intuitive, and empowering.